12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Plasmin: Phase I data

Data from 78 evaluable patients in an open-label, dose-escalation, U.S. Phase I trial showed that single doses of 25-175 mg catheter-delivered plasmin into the thrombus led to >=1 serious adverse event in 19 (23%) patients, major bleeding in 4 (4.8%) patients and minor bleeding in 13 (15.7%)...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >